Prof. Karim Fizazi is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France, and full Professor in Oncology at the University of Paris. Prof. Fizazi is currently involved in many phase II and phase III clinical trials as a principal investigator. These include GETUG 12 (a 400 patients National phase III trial testing docetaxel–estramustine in high risk localized prostate cancer whose accrual is now completed), GETUG 13 (an ongoing international trial in poor-prognosis non seminomatous germ-cell tumours), GIP-TG (a National ongoing phase II trial testing gemcitabine, ifosfamide and cisplatin in relapsed germ-cell tumors) and numerous industry-sponsored clinical trials, including the denosumab versus zoledronic acid (103 study), the docetaxel-ZD 4054 (Enthuse 33), and the docetaxel-lenalidomide (Mainsail) large phase III trials in prostate cancer.
In 1995 Prof. Fizazi attained his medical degree and he completed a Fellowship in 1997 (both in medical oncology). Prof. Fizazi gained his PhD in molecular oncology in 2003. He was appointed head of the Department of Medical Oncology at Institut Gustave Roussy in 2005 and full Professor at the University of Paris in 2009. A member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), Prof. Fizazi is the President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI) and is a member of the Urogenital Tumours Study Group (GETUG). Prof. Fizazi is associate editor of Annals of Oncology. He has authored numerous posters and abstracts at international congresses and has published over 100 peer-reviewed articles.